Altana AG

ots Ad hoc-Service: Altana AG

Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. ----------------------------------------------------- Konstanz (ots Ad hoc-Service) - The pharmaceuticals group of ALTANA AG, Byk Gulden (Constance), announces that one of the two phase III studies on LSF (Lung Surfactant) for the treatment of shock lung has been evaluated. The results do not meet expectations, so that the project in its current form is endangered and its schedule questioned. The results are now being discussed with the clinical testing doctors involved. The significance of this special product for rare indications (orphan drug) is low in terms of the estimated sales potential. WKN: 760080; Index: MDAX Listed: Amtlicher Handel in Frankfurt, Düsseldorf und Berlin; Freiverkehr in Bremen, Hamburg, Hannover, München und Stuttgart End ----------------------------------------------------- Internet: Original-Content von: Altana AG, übermittelt durch news aktuell

Das könnte Sie auch interessieren: